01—Abstract
Summary
Summary of the 10-K filed February 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported its seventh consecutive year of annual profitability in 2023, with net income of $207.8 milliona ($0.65 per share, basic and diluted), compared with $182.3 million in 2022.
Total revenues were $1,830.2 millionb versus $1,611.1 million, and net product revenues were $1,628.9 million, up 16% year over year. CABOMETYX drove the result, with net product revenues of $1,614.9 million, and the filing attributes the growth to a 9% increase in units sold following the FDA approval of CABOMETYX in combination with nivolumab for first-line advanced RCC, plus a 7% increase in average net selling price. Royalties earned on ex-U.S. cabozantinib sales were $148.5 million, up from $121.4 million.
Operating expenses rose, with research and development expenses of $1,044.1 millionc (versus $891.8 million) and selling, general and administrative expenses of $542.7 million (versus $459.9 million). Interest income more than doubled to $86.5 million. Cash, cash equivalents and investments totaled $1.7 billion at year-end, down from $2.1 billion, mainly because the company repurchased $550.4 million of common stock during 2023.
In January 2024 the Board authorized a further repurchase of up to $450.0 milliond and the company announced a restructuring that reduces its workforce by about 175 employees, or 13% of headcount, and terminates several research collaborations. The pipeline's key near-term events include the CONTACT-02 phase 3 trial in mCRPC, which met one of two primary endpoints (PFS), with overall survival still pending; the CABINET phase 3 trial in neuroendocrine tumors, where the company is discussing a potential FDA submission in 2024; and the zanzalintinib program, now in phase 3 trials.
Investors should also note the risk from generic competition: ANDAs from MSN, Teva and Cipla challenge CABOMETYX patents, and the company settled with Teva in July 2023 on a license effective January 1, 2031. The MSN II bench trial occurred in October 2023 with judgment expected in the first half of 2024.
02—Key points
Key Highlights
- Seventh consecutive year of annual profitability: net income of $207.8 million, or $0.65 per share, basic and diluted, versus $182.3 million in 2022.
- Total revenues rose to $1,830.2 million from $1,611.1 million; net product revenues grew 16% to $1,628.9 million, led by CABOMETYX at $1,614.9 million.
- Ex-U.S. cabozantinib royalties reached $148.5 million in 2023, up from $121.4 million, with Ipsen royalties of $135.8 million.
- The company repurchased $550.4 million of common stock in 2023 and authorized up to $450.0 million in additional repurchases in January 2024.
- January 2024 restructuring reduces the workforce by approximately 175 employees (13% of headcount) and terminates several research collaborations, with the company expecting lower R&D and SG&A expenses in 2024.
- Key pipeline catalysts include CONTACT-02 (met one of two primary PFS endpoints; OS analysis expected in 2024), CABINET in pNET/epNET (planned FDA discussions in 2024), and zanzalintinib in phase 3 trials.
- Generic competition risk: MSN, Teva and Cipla ANDAs challenge CABOMETYX patents; Teva settled with a U.S. license effective January 1, 2031, and a judgment in the MSN II case is expected in the first half of 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2023, Exelixis kept $0.11.
- Revenue$1.83B100.0%
- Cost of revenue−$72.5M4.0%
- Gross profit$1.76B96.0%
- Operating costs−$1.59B86.7%
- Operating income$170.9M9.3%
- Interest, other & tax$36.9M2.0%
- Net income$207.8M11.4%
Where FY2023 revenue went
$1.83B- R&D: $1.04B, 57% of revenue
- SG&A: $542.7M, 30% of revenue
- Operating income: $170.9M, 9.3% of revenue
- Cost of revenue: $72.5M, 4.0% of revenue
Kept 9.3% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 6, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $1.83B$1.61B | +13.6% |
| Cost of Revenue | $72.55M$57.91M | +25.3% |
| Gross Profit | $1.76B$1.55B | +13.2% |
| R&D Expenses | $1.04B$891.81M | +17.1% |
| SG&A Expenses | $542.71M$459.86M | +18.0% |
| Operating Expenses | $1.66B$1.41B | +17.7% |
| Operating Income | $170.88M$201.48M | −15.2% |
| Net Income | $207.80M$182.30M | +14.0% |
| EPS (Basic) | $0.65$0.57 | +14.0% |
| EPS (Diluted) | $0.65$0.56 | +16.1% |
| Shares Outstanding (Basic) | 318.15M321.53M | −1.0% |
| Shares Outstanding (Diluted) | 321.46M324.56M | −1.0% |
05—Questions
Frequently Asked Questions
How did Exelixis perform financially in 2023?
Exelixis reported net income of $207.8 million ($0.65 per share) for 2023, compared with $182.3 million in 2022. Total revenues increased to $1,830.2 million from $1,611.1 million, and net product revenues rose 16% to $1,628.9 million.
What drove the growth in CABOMETYX sales?
The filing attributes the increase in net product revenues mainly to a 9% rise in CABOMETYX units sold after the FDA approved CABOMETYX in combination with nivolumab as a first-line treatment for advanced RCC, and to a 7% increase in average net selling price.
What are the main risks to CABOMETYX revenue?
The filing identifies generic competition as a key risk. MSN, Teva and Cipla have filed ANDAs seeking to market generic CABOMETYX tablets, and the company has filed patent infringement suits against each. A July 2023 settlement with Teva grants Teva a U.S. license beginning January 1, 2031. The company also cites pricing pressure from the Inflation Reduction Act and 340B Program litigation.
What changed in the company's cash position and capital allocation?
Cash, cash equivalents and investments fell to $1.7 billion at December 31, 2023, from $2.1 billion, mainly due to $550.4 million in share repurchases. In January 2024 the Board authorized up to $450.0 million in further repurchases to be completed by the end of 2024.
What near-term pipeline events should investors watch?
The filing points to the CONTACT-02 overall survival analysis expected in 2024, the company's planned discussions with the FDA on a potential CABINET regulatory submission in 2024, the next OS analysis for COSMIC-313, and ongoing phase 3 trials of zanzalintinib (STELLAR-303, STELLAR-304 and STELLAR-305).
06—Continue